title: Chronic exposure to anabolic steroids induces the muscle expression of oxytocin and a more than fiftyfold increase in circulating oxytocin in cattle.
abstract: Molecular mechanisms in skeletal muscle associated with anabolic steroid treatment of cattle are unclear and we aimed to characterize transcriptional changes. Cattle were chronically exposed (68 ± 20 days) to a steroid hormone implant containing 200 mg trenbolone acetate and 20 mg estradiol (Revalor-H). Biopsy samples from 48 cattle (half treated) from longissimus dorsi (LD) muscle under local anesthesia were collected. Gene expression levels were profiled by microarray, covering 16,944 unique bovine genes: 121 genes were differentially expressed (DE) due to the implant (99.99% posterior probability of not being false positives). Among DE genes, a decrease in expression of a number of fat metabolism-associated genes, likely reflecting the lipid storage activity of intramuscular adipocytes, was observed. The expression of IGF1 and genes related to the extracellular matrix, slow twitch fibers, and cell cycle (including SOX8, a satellite cell marker) was increased in the treated muscle. Unexpectedly, a very large 21- (microarray) to 97 (real time quantitative PCR)-fold higher expression of the mRNA encoding the neuropeptide hormone oxytocin was observed in treated muscle. We also observed an ∼50-fold higher level of circulating oxytocin in the plasma of treated animals at the time of biopsy. Using a coexpression network strategy OXTR was identified as more likely than IGF1R to be a major mediator of the muscle response to Revalor-H. A re-investigation of in vivo cattle LD muscle samples during early to mid-fetal development identified a >128-fold increased expression of OXT, coincident with myofiber differentiation and fusion. We propose that oxytocin may be involved in mediating the anabolic effects of Revalor-H treatment.
authors.affiliation: Australian Cooperative Research Centre for Beef Genetic Technologies, University of New England, Armidale, New South Wales.
authors.forename: Nadia
authors.initials: N
authors.lastname: De Jager
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Hudson
authors.forename: Antonio
authors.initials: A
authors.lastname: Reverter
authors.forename: Yong-Hong
authors.initials: YH
authors.lastname: Wang
authors.forename: Shivashankar H
authors.initials: SH
authors.lastname: Nagaraj
authors.forename: Linda M
authors.initials: LM
authors.lastname: Cafe
authors.forename: Paul L
authors.initials: PL
authors.lastname: Greenwood
authors.forename: Ross T
authors.initials: RT
authors.lastname: Barnard
authors.forename: Kritaya P
authors.initials: KP
authors.lastname: Kongsuwan
authors.forename: Brian P
authors.initials: BP
authors.lastname: Dalrymple
mesh_terms: D045930:Anabolic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D002417:Cattle; D004958:Estradiol / Q000008:administration & dosage* / Q000494:pharmacology; D046228:Microarray Analysis; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism*; D010121:Oxytocin / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000378:metabolism; D014204:Trenbolone Acetate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D045930:Anabolic Agents; D012333:RNA, Messenger; D004958:Estradiol; D010121:Oxytocin; D014204:Trenbolone Acetate